Literature DB >> 18213620

Risk of hypothyroidism in older breast cancer patients treated with radiation.

Grace L Smith1, Benjamin D Smith, Sharon H Giordano, Ya Chen T Shih, Wendy A Woodward, Eric A Strom, George H Perkins, Welela Tereffe, Tse Kuan Yu, Thomas A Buchholz.   

Abstract

BACKGROUND: Hypothyroidism is a potential complication after radiation therapy (RT) when treatment fields include the thyroid. The authors assessed risk of hypothyroidism in breast cancer patients who were receiving RT to a supraclavicular field, which typically includes a portion of thyroid.
METHODS: The authors identified 38,255 women (aged>65) without history of hypothyroidism from the Surveillance, Epidemiology, and End Results (SEER)-Medicare cohort diagnosed with stage 0-III breast cancer from 1992-2002 and 111,944 cancer-free controls. The authors compared hypothyroidism incidence among irradiated patients with 4+positive lymph nodes (4+LN, surrogate for supraclavicular RT) and no positive nodes (0 LN, surrogate for no supraclavicular RT), nonirradiated patients, and controls. Proportional hazards models tested associations of LN, RT, and breast cancer status with hypothyroidism.
RESULTS: The 5-year incidence of hypothyroidism was identical (14%) in irradiated patients with 4+LN, 0 LN, and nonirradiated patients (P=.52). After adjusting for sociodemographic and clinical characteristics, hypothyroidism risk was not increased in irradiated patients with 4+LN versus 0 LN (hazard ratio(HR)=1.04; 95% confidence interval (CI), 0.89-1.23). However, all patients, regardless of RT status, were more likely to be diagnosed with hypothyroidism compared with cancer-free controls (HR=1.21; 95% CI, 1.17-1.25).
CONCLUSIONS: Development of hypothyroidism is fairly common in older breast cancer survivors. Although supraclavicular irradiation does not appear to amplify risks, further studies on the role of routine thyroid function monitoring in all breast cancer patients regardless of treatment status may be warranted, given the excess risks compared with the general population. Copyright (c) 2008 American Cancer Society.

Entities:  

Mesh:

Year:  2008        PMID: 18213620     DOI: 10.1002/cncr.23307

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Targeting of ALK2, a Receptor for Bone Morphogenetic Proteins, Using the Cre/lox System to Enhance Osseous Regeneration by Adipose-Derived Stem Cells.

Authors:  Jonathan R Peterson; Oluwatobi Eboda; Shailesh Agarwal; Kavitha Ranganathan; Steven R Buchman; Min Lee; Stewart C Wang; Yuji Mishina; Benjamin Levi
Journal:  Stem Cells Transl Med       Date:  2014-09-17       Impact factor: 6.940

2.  The influence of comorbidities on overall survival among older women diagnosed with breast cancer.

Authors:  Jennifer L Patnaik; Tim Byers; Carolyn Diguiseppi; Thomas D Denberg; Dana Dabelea
Journal:  J Natl Cancer Inst       Date:  2011-06-30       Impact factor: 13.506

3.  Incidence of hypothyroidism after treatment for breast cancer: A Korean population-based study.

Authors:  Jongmoo Park; Choongrak Kim; Yongkan Ki; Wontaek Kim; Jiho Nam; Donghyun Kim; Dahl Park; Hosang Jeon; Dong Woon Kim; Ji Hyeon Joo
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

4.  TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001).

Authors:  Ilaria Muller; Lucy S Kilburn; Peter N Taylor; Peter J Barrett-Lee; Judith M Bliss; Paul Ellis; Marian E Ludgate; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2017-04-04

5.  Racial disparities in the use of radiotherapy after breast-conserving surgery: a national Medicare study.

Authors:  Grace L Smith; Ya-Chen T Shih; Ying Xu; Sharon H Giordano; Benjamin D Smith; George H Perkins; Welela Tereffe; Wendy A Woodward; Thomas A Buchholz
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

6.  A method to predict breast cancer stage using Medicare claims.

Authors:  Grace L Smith; Ya-Chen T Shih; Sharon H Giordano; Benjamin D Smith; Thomas A Buchholz
Journal:  Epidemiol Perspect Innov       Date:  2010-01-15

7.  Evaluation of thyroid gland as an organ at risk after breast cancer radiotherapy: a systematic review and meta-analysis.

Authors:  L Darvish; M Ghorbani; S Hosseini Teshnizi; N Roozbeh; F Seif; M Reza Bayatiani; C Knaup; A Amraee
Journal:  Clin Transl Oncol       Date:  2018-05-14       Impact factor: 3.405

8.  Dose distribution in the thyroid gland following radiation therapy of breast cancer--a retrospective study.

Authors:  S Johansen; K V Reinertsen; K Knutstad; D R Olsen; S D Fosså
Journal:  Radiat Oncol       Date:  2011-06-09       Impact factor: 3.481

9.  Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.

Authors:  N F Khan; D Mant; L Carpenter; D Forman; P W Rose
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

10.  Thyroid disorders and breast cancer risk in Asian population: a nationwide population-based case-control study in Taiwan.

Authors:  Chien-Hsiang Weng; Yi-Huei Chen; Ching-Heng Lin; Xun Luo; Tseng-Hsi Lin
Journal:  BMJ Open       Date:  2018-03-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.